PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8 IN COMPARISON TO NPH AND PREMIX IN POLAND?
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66687-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)66687-9/fulltext
Title :
PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8 IN COMPARISON TO NPH AND PREMIX IN POLAND?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66687-9&doi=10.1016/S1098-3015(10)66687-9
First page :
Section Title :
Open access? :
No
Section Order :
521